Suzhou Ribo Life Science Co., Ltd. (Ribo) is a company dedicated to discovering, developing and commercializing innovative oligonucleotide therapeutics (mainly siRNA, also ASO and aptamer), and is the pioneer and leading player in this sector in China.
Ribo has built a vertically integrated R&D platform including various aspects of proprietary technologies, facilities and a highly qualified professional team that have enabled the development of a significant pipeline of oligonucleotide therapeutics.
Ribo signed up with Boehringer Ingelheim to develop new treatments for people with liver diseases.
Ribo granted Qilu Pharmaceutical Co., Ltd. the rights to develop, manufacture and commercialize RBD7022 in Greater China region.
Ribo acquired the exclusive rights to develop, manufacture and commercialize anti-VEGF/Ang2 bispecific aptamer licensed from Aptitude Medical Systems Inc. in Greater China.
Ribo acquired the exclusive rights to develop, manufacture and commercialize 3 antisense oligonucleotide therapeutics licensed from Ionis Pharmaceuticals Inc. in China.
Ribo acquired the exclusive rights to develop, manufacture and commercialize BT-200 licensed from Band Therapeutics Inc. in Greater China.
Ribo obtained the rights licensed from Life Technologies, Inc. (acquired by Thermo Fisher Scientific in 2014) to apply the liposome delivery technology for development of oligonucleotide therapeutics in China.
Ribo entered into a strategic partnership with Quark Pharmaceuticals Inc. to fuel the development and commercialization of RNAi drugs in most of Asian countries.